Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242115571 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lei Zhai und 18 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia. Hauptthemen laut MEDLINE: Antimitotic Agents, Neuroblastoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCD NIH HHS, National Health and Medical Research Council (NHMRC) Australia, Priority-driven Collaborative Cancer Research Scheme.
Abstract (Originalsprache)
MYCN amplification occurs in approximately 20–30% of neuroblastoma patients and correlates with poor prognosis. The TH-MYCN transgenic mouse model mimics the development of human high-risk neuroblastoma and provides strong evidence for the oncogenic function of MYCN. In this study, we identified mitotic dysregulation as a hallmark of tumor initiation in the pre-cancerous ganglia from TH-MYCN mice that persists through tumor progression. Single-cell quantitative-PCR of coeliac ganglia from 10-day-old TH-MYCN mice revealed overexpression of mitotic genes in a subpopulation of premalignant neuroblasts at a level similar to single cells derived from established tumors. Prophylactic treatment using antimitotic agents barasertib and vincristine significantly delayed the onset of tumor formation, reduced pre-malignant neuroblast hyperplasia, and prolonged survival in TH-MYCN mice. Analysis of human neuroblastoma tumor cohorts showed a strong correlation between dysregulated mitosis and features of MYCN amplification, such as MYC(N) transcriptional activity, poor overall survival, and other clinical predictors of aggressive disease. To explore the therapeutic potential of targeting mitotic dysregulation, we showed that genetic and chemical inhibition of mitosis led to selective cell death in neuroblastoma cell lines with MYCN over-expression. Moreover, combination therapy with antimitotic compounds and BCL2 inhibitors exploited mitotic stress induced by antimitotics and was synergistically toxic to neuroblastoma cell lines. These results collectively suggest that mitotic dysregulation is a key component of tumorigenesis in early neuroblasts, which can be inhibited by the combination of antimitotic compounds and pro-apoptotic compounds in MYCN-driven neuroblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Cancer Institute Australia, Lowy Cancer Research Centre, University of New South Wales, Randwick, NSW 2031, Australia.
- Adult Cancer Program, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW 2031, Australia.
- Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
- School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
- Department of Biomolecular Medicine, Cancer Research Institute Ghent, Ghent University, 9000 Ghent, Belgium.
- UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW 2031, Australia.
ORCID-Profile: Shoma Tsubota, Anneleen Beckers, Kaat Durink, Katleen De Preter, Frank Speleman, Murray D Norris, Belamy B Cheung
Förderung
- NIDCD NIH HHS
- National Health and Medical Research Council (NHMRC) Australia
- Priority-driven Collaborative Cancer Research Scheme
- Cancer Institute NSW Early Career Fellowship
- NHMRC Australia
- Cancer Institute NSW
Zitieren
APA
Zhai, L., Balachandran, A., Larkin, R., Seneviratne, J. A., Chung, S. A., Lalwani, A., Tsubota, S., Beck, D., Kadomatsu, K., Beckers, A., Durink, K., De Preter, K., Speleman, F., Haber, M., Norris, M. D., Swarbrick, A., Cheung, B. B., Marshall, G. M., & Carter, D. R. (2023). Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115571
Vancouver
Zhai L, Balachandran A, Larkin R, Seneviratne JA, Chung SA, Lalwani A, et al. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115571
BibTeX
@article{Zhai2023,
author = {Zhai, Lei and Balachandran, Anushree and Larkin, Rebecca and Seneviratne, Janith A and Chung, Sylvia A and Lalwani, Amit and Tsubota, Shoma and Beck, Dominik and Kadomatsu, Kenji and Beckers, Anneleen and Durink, Kaat and De Preter, Katleen and Speleman, Frank and Haber, Michelle and Norris, Murray D and Swarbrick, Alexander and Cheung, Belamy B and Marshall, Glenn M and Carter, Daniel R},
title = {Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242115571}
}
EUVIMED